Infectious Disease Molecular Diagnostics Market Report 2025

The infectious disease molecular diagnostics market size has grown strongly in recent years. It will grow from $28.95 billion in 2024 to $30.46 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth during the historic period can be attributed to the increasing prevalence of infectious diseases, growing demand for early and accurate diagnosis, the rise in global outbreaks and pandemics, enhanced healthcare awareness and access, and increased investment in diagnostic research and technology.

The infectious disease molecular diagnostics market size is expected to see strong growth in the next few years. It will grow to $36.98 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The growth projected for the forecast period can be attributed to the increasing adoption of point-of-care testing, a stronger focus on personalized medicine, rising government support for infectious disease control, expanding healthcare infrastructure in emerging markets, and the growing prevalence of respiratory diseases. Key trends expected during this period include advancements in real-time polymerase chain reaction technology, enhanced integration of artificial intelligence in diagnostic platforms, development of multiplex testing panels, innovations in portable and home-based diagnostic kits, and progress in automating molecular diagnostic workflows.

The rising prevalence of infectious diseases is expected to drive growth in the infectious disease molecular diagnostics market going forward. Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, which can be transmitted directly or indirectly between people. The increase in infectious diseases is mainly due to globalization and higher travel rates, enabling pathogens to spread quickly across borders and turn localized outbreaks into global health crises. Molecular diagnostics for infectious diseases support disease management by providing rapid and accurate detection of pathogens at the genetic level, which aids early diagnosis, targeted treatment, and effective outbreak control. For example, according to the US Centers for Disease Control and Prevention, in 2022, the United States reported 8,331 tuberculosis (TB) cases, reflecting a 5.9% increase compared to 2021. Therefore, the growing prevalence of infectious diseases is fueling the expansion of the infectious disease molecular diagnostics market.

Leading companies in the infectious disease molecular diagnostics market are concentrating on developing innovative solutions such as real-time polymerase chain reaction (PCR) kits, which enable rapid, accurate, and high-throughput detection of infectious pathogens. Real-time PCR kits amplify and detect specific genetic material of pathogens simultaneously in real time, allowing for fast and precise identification of infectious diseases. For instance, in February 2023, Thermo Fisher Scientific Inc., a US-based biotechnology and life sciences company, introduced Applied Biosystems TaqPath PCR kits for infectious disease detection in India. These kits offer fast, highly sensitive multiplex diagnostic solutions that perform real-time PCR detection of infectious disease targets through a complete workflow - from ribonucleic acid extraction to diagnostic report generation, typically within four hours. The kits include multiplexed assays targeting multiple pathogen genomic regions, internal process controls, and automated data interpretation, which reduces user error and improves reliability of results.

In May 2024, Bruker Corporation, a US-based scientific instrument and analytical technology company, acquired ELITechGroup for $0.94 billion. Through this acquisition, Bruker Corporation aims to enhance its expertise in infectious disease diagnostics by obtaining access to advanced sample-to-answer molecular diagnostic systems and an extensive portfolio of infectious disease assays that complement its existing products. ELITechGroup SAS is a France-based company specializing in infectious disease molecular diagnostics.

Major players in the infectious disease molecular diagnostics market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Agilent Technologies Inc., Hologic Inc., Illumina Inc., Biomerieux S.A., Quidel Ortho Corporation, Sysmex Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A., Seegene Inc., Oxford Nanopore Technologies plc, Biocartis NV, T2 Biosystems Inc., and Sherlock Biosciences Inc.

North America was the largest region in the infectious disease molecular diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in infectious disease molecular diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the infectious disease molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The infectious disease molecular diagnostics market consists of revenues earned by entities by providing services such as polymerase chain Reaction (PCR) testing, next-generation sequencing, isothermal nucleic acid amplification tests, point-of-care (POC) molecular testing, and viral load monitoring and resistance testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The infectious disease molecular diagnostics market also includes sales of nucleic acid extraction systems, isothermal amplification assays, multiplex diagnostic panels, molecular diagnostic reagents and consumables, and bloodborne pathogen detection kits. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The infectious disease molecular diagnostics market research report is one of a series of new reports that provides infectious disease molecular diagnostics market statistics, including infectious disease molecular diagnostics global market size, regional shares, competitors with infectious disease molecular diagnostics market share, detailed infectious disease molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the infectious disease molecular diagnostics industry. The infectious disease molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Infectious disease molecular diagnostics involves advanced laboratory methods used to detect and identify genetic material from pathogens like bacteria, viruses, fungi, or parasites in patient samples. These diagnostics facilitate rapid and precise diagnosis of infectious diseases, enabling timely treatment and effective disease management.

The primary product categories in infectious disease molecular diagnostics include kits and reagents, instruments, software, and services. Kits and reagents consist of pre-packaged chemical and biological components designed for specific laboratory tests or procedures, such as detecting, measuring, or amplifying genetic material, proteins, or pathogens. Key technologies employed in this area include polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification, chips and microarrays, mass spectrometry, transcription-mediated amplification, among others. These tools are applied to a variety of conditions, including respiratory diseases, tuberculosis, meningitis, gastrointestinal infections, human papillomavirus, sexually transmitted infections, sepsis, and drug-resistant diseases. End users include hospitals and clinical laboratories, diagnostic labs, pharmaceutical companies, and academic and research institutions.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.